Lexaria Bioscience Corp Report Results From Its 2023 Human Oral Nicotine Study NIC-H22-1 Comparing Lexaria's DehydraTECH-Nicotine Tobacco-Free Pouch To ZYN
Portfolio Pulse from Benzinga Newsdesk
Lexaria Bioscience Corp has reported results from its 2023 human oral nicotine study NIC-H22-1. The study compared Lexaria's DehydraTECH-Nicotine tobacco-free pouch to ZYN.
August 09, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The results of Lexaria Bioscience Corp's human oral nicotine study could potentially impact the company's stock.
The results of the study could potentially influence the company's stock price. If the results are positive, it could increase investor confidence in the company's products and potentially lead to a rise in the stock price. Conversely, if the results are negative, it could decrease investor confidence and potentially lead to a drop in the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100